Hyperfine Inc.
08/10/2022 | Press release | Distributed by Public on 08/10/2022 14:17
Hyperfine Reports Second Quarter 2022 Financial Results - Form 8-K
Hyperfine Reports Second Quarter 2022 Financial Results
GUILFORD, Connecticut, August 10, 2022 (GLOBE NEWSWIRE) - Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today reported financial results for the quarter ended June 30, 2022. Management will host a corresponding conference call today at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
"We continue to build awareness of Swoop's immense value proposition, deepen our customer relationships, and drive adoption in new hospitals," said Scott Huennekens, Interim President and CEO of Hyperfine. "We placed 9 commercial systems in the second quarter, including through our recent expansion to Australia and New Zealand - a new geography for Hyperfine - and we continue to build our pipeline for the second half of the year and beyond."
Second Quarter 2022 Financial Results
•
Revenues for the second quarter of 2022 were $1.533 million, compared to $0.358 million in the second quarter of 2021.
•
Gross margin for the second quarter of 2022 was $(0.165) million, compared to $(0.099) million in the second quarter of 2021.
•
Research and development expenses for the second quarter of 2022 were $7.265 million, compared to $6.037 million in the second quarter of 2021.
•
Sales, marketing, general, and administrative expenses for the second quarter of 2022 were $15.762 million, compared to $8.450 million in the second quarter of 2021.
•
Net loss for the second quarter was $23.159 million, equating to a net loss of $0.33 per share, as compared to a net loss of $14.580 million, or a net loss of $8.80 per share, for the second quarter of 2021.
Six Months Financial Results
•
Revenues for the six months ended June 30, 2022 were $3.042 million, compared to $0.689 million in the six months ended June 30, 2021.
•
Gross margin for the six months ended June 30, 2022 was $(0.081) million, compared to $(0.376) million in the six months ended June 30, 2021.
•
Research and development expenses for the six months ended June 30, 2022 were $15.599 million, compared to $10.511 million in the six months ended June 30, 2021.
•
Sales, marketing, general, and administrative expenses for the six months ended June 30, 2022 were $31.283 million, compared to $11.504 million in the six months ended June 30, 2021.
•
Net loss for the six months ended June 30, 2022 was $46.934 million, equating to a net loss of $0.67 per share, as compared to a net loss of $22.374 million, or a net loss of $13.72 per share, for the six months ended June 30, 2021.
Commercial System Installations
•
Hyperfine installed 9 commercial Swoop systems in the second quarter, bringing total year-to-date commercial installations* to 20 systems.
•
Hyperfine has now installed 47 commercial systems launch-to-date and maintains a total installed base* of 92 systems globally.
* The Swoop total installed base consists of three components: Commercial system installations (which make up total revenue), grant fulfillment installations, and research unit installations. The Swoop total installed base (or total installed units) is the number of Swoop devices deployed to hospitals, other healthcare providers, and research institutions. We view the total installed base as a key metric of the growth of our business and is measured from period over period.
Recent Strategic Highlights
•
Received FDA 510(k) clearances for multiple Swoop system enhancements including two new imaging sequences which expand system capabilities using deep learning (DL) and allow shorter brain scan times for patients, as well as improved patient positioning based on customer feedback.
•
Launched a partnership with Viz.ai, a leading AI-powered disease detection and intelligent care coordination platform, to bring MRI to the patient's bedside and deliver valuable insights to the clinician's fingertips for timely decision making. Hyperfine and Viz.ai intend to focus on patient care in neuro ICUs to further decrease the time from admission to treatment by expediting clinician access to MRI imaging and increasing access to time-critical diagnostics in the acute and post-acute care phase.
2022 Financial Guidance
•
Management expects revenue for the full year 2022 to be $7 million to $8 million.
•
Management expects 35 to 45 commercial units installed in 2022.
Conference Call
Hyperfine will host a conference call at 1:30 p.m. PST / 4:30 p.m. ET today to discuss its second quarter 2022 financial results. Those interested in listening should register online by visiting https://investors.hyperfine.io/ and clicking on News & Events. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived audio webcast will be available through the Investors page of Hyperfine's corporate website at https://investors.hyperfine.io/.
About Hyperfine
Hyperfine, Inc. is the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™. Hyperfine designed Swoop to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. The Swoop Portable MR Imaging System™ produces high-quality images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient's bedside, plugged into a standard electrical wall outlet, and controlled by an iPad®. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments, operating rooms outside the sterile field, and intensive care units, among others.
|
Investor Contact |
|
Marissa Bych |
|
Gilmartin Group LLC |
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about Hyperfine's financial and operating results, the benefits of Hyperfine's products and services, and Hyperfine's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of Hyperfine's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of Hyperfine product development and commercialization activities, including the degree that Swoop is accepted and used by healthcare professionals; the impact of COVID-19 on Hyperfine's business; the inability to maintain the listing of Hyperfine's Class A common stock on the Nasdaq following the recently completed business combination; the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and Hyperfine's ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of Hyperfine to raise financing in the future; the inability of Hyperfine to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of Hyperfine to identify, in-license or acquire additional technology; the inability of Hyperfine to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of Hyperfine to compete with other companies currently marketing or engaged in the development of products and services that Hyperfine is currently marketing or developing; the size and growth potential of the markets for Hyperfine's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Hyperfine's products and services and reimbursement for medical procedures conducted using Hyperfine's products and services; Hyperfine's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; Hyperfine's financial performance; and other risks and uncertainties indicated from time to time in Hyperfine's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. Hyperfine cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. Hyperfine does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
HYPERFINE, INC. AND SUBSIDIARIES
CONDENSED COMBINED AND CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
|
June 30, |
December 31, |
|||
|
ASSETS |
||||
|
CURRENT ASSETS: |
||||
|
Cash and cash equivalents |
$ |
145,104 |
$ |
188,498 |
|
Restricted cash |
1,604 |
2,662 |
||
|
Accounts receivable, net |
1,987 |
553 |
||
|
Unbilled receivables |
1,118 |
91 |
||
|
Inventory |
4,646 |
4,310 |
||
|
Prepaid expenses and other current assets |
2,570 |
1,357 |
||
|
Due from related parties |
2 |
14 |
||
|
Total current assets |
$ |
157,031 |
$ |
197,485 |
|
Property and equipment, net |
3,498 |
3,753 |
||
|
Other long term assets |
1,179 |
1,235 |
||
|
Total assets |
$ |
161,708 |
$ |
202,473 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||
|
CURRENT LIABILITIES: |
||||
|
Accounts payable |
$ |
1,697 |
$ |
2,248 |
|
Deferred grant funding |
1,604 |
2,662 |
||
|
Deferred revenue |
964 |
730 |
||
|
Due to related parties |
81 |
1,981 |
||
|
Accrued expenses and other current liabilities |
6,109 |
8,115 |
||
|
Total current liabilities |
$ |
10,455 |
$ |
15,736 |
|
Long term deferred revenue |
745 |
510 |
||
|
Total liabilities |
$ |
11,200 |
$ |
16,246 |
|
COMMITMENTS AND CONTINGENCIES |
||||
|
STOCKHOLDERS' EQUITY |
||||
|
Class A Common stock, $.0001 par value; 600,000,000 shares authorized; 55,312,656 and 55,277,061 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively |
5 |
5 |
||
|
Class B Common stock, $.0001 par value; 27,000,000 shares authorized; 15,055,288 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively |
2 |
2 |
||
|
Additional paid-in capital |
333,755 |
322,540 |
||
|
Accumulated deficit |
(183,254 |
) |
(136,320 |
) |
|
Total stockholders' equity |
$ |
150,508 |
$ |
186,227 |
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
161,708 |
$ |
202,473 |
HYPERFINE, INC. AND SUBSIDIARIES
CONDENSED COMBINED AND CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(Unaudited)
|
Three months ended June 30, |
Six months ended June 30, |
|||||||||||
|
2022 |
2021 |
2022 |
2021 |
|||||||||
|
Sales |
||||||||||||
|
Device |
$ |
1,168 |
$ |
152 |
$ |
2,360 |
$ |
321 |
||||
|
Service |
365 |
206 |
682 |
368 |
||||||||
|
Total sales |
$ |
1,533 |
$ |
358 |
$ |
3,042 |
$ |
689 |
||||
|
Cost of sales |
||||||||||||
|
Device |
$ |
1,259 |
$ |
364 |
$ |
2,296 |
$ |
912 |
||||
|
Service |
439 |
93 |
827 |
153 |
||||||||
|
Total cost of sales |
$ |
1,698 |
$ |
457 |
$ |
3,123 |
$ |
1,065 |
||||
|
Gross margin |
(165 |
) |
(99 |
) |
(81 |
) |
(376 |
) |
||||
|
Operating Expenses: |
||||||||||||
|
Research and development |
$ |
7,265 |
$ |
6,037 |
$ |
15,599 |
$ |
10,511 |
||||
|
General and administrative |
12,012 |
6,663 |
23,372 |
8,521 |
||||||||
|
Sales and marketing |
3,750 |
1,787 |
7,911 |
2,983 |
||||||||
|
Total operating expenses |
23,027 |
14,487 |
46,882 |
22,015 |
||||||||
|
Loss from operations |
$ |
(23,192 |
) |
$ |
(14,586 |
) |
$ |
(46,963 |
) |
$ |
(22,391 |
) |
|
Interest income |
$ |
32 |
$ |
5 |
$ |
33 |
$ |
10 |
||||
|
Other income (expense), net |
1 |
1 |
(4 |
) |
7 |
|||||||
|
Loss before provision for income taxes |
$ |
(23,159 |
) |
$ |
(14,580 |
) |
$ |
(46,934 |
) |
$ |
(22,374 |
) |
|
Provision for income taxes |
- |
- |
- |
- |
||||||||
|
Net loss and comprehensive loss |
$ |
(23,159 |
) |
$ |
(14,580 |
) |
$ |
(46,934 |
) |
$ |
(22,374 |
) |
|
Net loss per common share attributable to common stockholders, basic and diluted |
$ |
(0.33 |
) |
$ |
(8.80 |
) |
$ |
(0.67 |
) |
$ |
(13.72 |
) |
|
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted |
70,350,178 |
1,657,345 |
70,341,411 |
1,630,190 |
HYPERFINE, INC. AND SUBSIDIARIES
CONDENSED COMBINED AND CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
(Unaudited)
|
Six months ended June 30, |
||||||
|
2022 |
2021 |
|||||
|
Cash flows from operating activities: |
||||||
|
Net loss |
$ |
(46,934 |
) |
$ |
(22,374 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||
|
Depreciation and amortization |
516 |
218 |
||||
|
Stock-based compensation expense |
11,213 |
1,756 |
||||
|
Write-down of inventory |
- |
33 |
||||
|
Payments received on net investment in lease |
4 |
5 |
||||
|
Changes in assets and liabilities: |
||||||
|
Accounts receivable |
(1,434 |
) |
(263 |
) |
||
|
Unbilled receivables |
(1,027 |
) |
(39 |
) |
||
|
Inventory |
(336 |
) |
(449 |
) |
||
|
Prepaid expenses and other current assets |
(1,213 |
) |
(357 |
) |
||
|
Due from related parties |
12 |
1,279 |
||||
|
Other assets - related party |
- |
193 |
||||
|
Other long term assets |
52 |
(20 |
) |
|||
|
Accounts payable |
(551 |
) |
196 |
|||
|
Deferred grant funding |
(1,058 |
) |
(322 |
) |
||
|
Deferred revenue |
469 |
554 |
||||
|
Due to related parties |
(1,900 |
) |
(50 |
) |
||
|
Accrued expenses and other current liabilities |
(2,013 |
) |
536 |
|||
|
Net cash used in operating activities |
$ |
(44,200 |
) |
$ |
(19,104 |
) |
|
Cash flows from investing activities: |
||||||
|
Purchases of fixed assets |
(254 |
) |
(675 |
) |
||
|
Net cash used in investing activities |
$ |
(254 |
) |
$ |
(675 |
) |
|
Cash flows from financing activities: |
||||||
|
Proceeds from exercise of stock options |
2 |
198 |
||||
|
Proceeds from issuance of Series D convertible preferred stock |
- |
30,468 |
||||
|
Stock issuance costs related to Series D convertible preferred stock |
- |
(7 |
) |
|||
|
Investment from 4Bionics, LLC |
- |
3,516 |
||||
|
Net cash provided by financing activities |
$ |
2 |
$ |
34,175 |
||
|
Net (decrease) increase in cash and cash equivalents and restricted cash |
(44,452 |
) |
14,396 |
|||
|
Cash, cash equivalents and restricted cash, beginning of period |
191,160 |
64,286 |
||||
|
Cash, cash equivalents and restricted cash, end of period |
$ |
146,708 |
$ |
78,682 |
||
|
Reconciliation of cash, cash equivalents, and restricted cash |
||||||
|
Cash and cash equivalents |
$ |
145,104 |
$ |
77,394 |
||
|
Restricted cash |
1,604 |
1,288 |
||||
|
Total cash, cash equivalents and restricted cash |
$ |
146,708 |
$ |
78,682 |
||
|
Supplemental disclosure of cash flow information: |
||||||
|
Cash received from exchange of research and development tax credits |
$ |
- |
$ |
324 |
||
|
Supplemental disclosure of noncash information: |
||||||
|
Write-off of notes receivable |
$ |
90 |
$ |
- |